Aduro Biotech Inc. (NASDAQ:ADRO) shares were up 3.7% on Friday . The company traded as high as $13.11 and last traded at $12.99, with a volume of 150,859 shares trading hands. The stock had previously closed at $12.53.

A number of research analysts recently weighed in on ADRO shares. FBR & Co reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Aduro Biotech in a research report on Monday, March 28th. Zacks Investment Research lowered Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Monday, March 28th. Leerink Swann reissued an “outperform” rating and issued a $14.00 target price (down previously from $48.00) on shares of Aduro Biotech in a report on Tuesday, May 17th. Roth Capital reissued a “buy” rating and issued a $46.00 target price on shares of Aduro Biotech in a report on Tuesday, March 22nd. Finally, Canaccord Genuity reissued a “buy” rating on shares of Aduro Biotech in a report on Monday, May 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $24.17.

The company has a 50 day moving average of $11.79 and a 200 day moving average of $14.43. The stock’s market capitalization is $843.82 million.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Monday, May 2nd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.20. On average, equities research analysts forecast that Aduro Biotech Inc. will post ($1.24) EPS for the current fiscal year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total value of $290,250.00. Following the completion of the sale, the insider now owns 13,939 shares in the company, valued at $161,831.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently bought a new stake in Aduro Biotech stock. ProShare Advisors LLC purchased a new position in shares of Aduro Biotech Inc. (NASDAQ:ADRO) during the fourth quarter, according to its most recent disclosure with the SEC. The fund purchased 51,296 shares of the company’s stock, valued at approximately $1,443,000. ProShare Advisors LLC owned 0.08% of Aduro Biotech at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.